Major investment interest in award-wining 1928 Diagnostics
Some 30 active investors provide MSEK 20 million for the diagnostics company which with its innovative software will fight the global threat of antibiotic resistance. These investments take place via Sciety who is specialised in growth companies within health and medicine.
With 1928 Diagnostic’s software, one can, on the basis of the technology already at the hospitals, analyse the DNA of bacteria to identify the types of antibiotics which are resistant and how the bacteria are spread. The software contributes to the digitisation of the diagnosis which has until now taken place through cultures, which takes a long time. With the help of this software, one can provide the correct treatment much more quickly which, in its turn, can lead to a more rapid recovery and the reduced use of antibiotics.
1928 Diagnostics was recently awarded a place on Ny Teknik’s 33 List and last autumn took second place in the DI Startup Tour with Sweden’s most prominent risk capital companies comprising the jury. The company is now working with the CE certification of the software to start sales and, at the same time, is further developing its contacts in Europe and the US.
Sciety is an investor network wanting life science innovations to reach their full potential and create value. Sciety offers capital market services with a focus on Swedish life science. We want innovations within the industry to reach their full potential.Sciety is an investor network with a focus Swedish growth companies within life science. If you wish to receive news about investment possibilities and invitations to presentations by companies’ management – apply here.